Aktie 902646 UROLOGIX, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Urologix, Inc. Other OTC

Aktien

902646

US9172731047

ULGX

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
A unknown buyer acquired substantially all of the operating assets of Urologix, Inc.
Urologix Conducting A Strategic Review
Urologix, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015
Urologix, Inc. Appoints Scott M. Madson as Chief Financial Officer Effective April 1, 2015
Urologix, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended December 31, 2014
Urologix, Inc. Announces Revenue Guidance for Second Quarter Ended on December 31, 2014
Urologix, Inc. Reports Unaudited Earnings Results for the First Quarter Ended September 30, 2014; Provides Cash Flow Guidance for the Fiscal 2015
Urologix, Inc. Announces Executive Changes
Urologix, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended June 30, 2014; Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2014; Provides Earnings Guidance for the Full Year 2015
Urologix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014
Urologix, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014
Urologix, Inc. Announces Preliminary Unaudited Revenue Results for the Third Quarter Ended March 31, 2014
Urologix Secures Extension of Credit Facility
Urologix, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended December 31, 2013
Urologix, Inc. Reports Revenue Results for the Second Quarter Ended December 31, 2013; Withdraws Previously Issued Fiscal Year 2014 Revenue Guidance
Urologix, Inc. Announces Unaudited Earnings Results for the First Quarter Ended September 30, 2013; Reaffirms Revenue Guidance for Fiscal 2014
Urologix, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended June 30, 2013; Provides Revenue Guidance for the Fiscal Year 2014; Reports Impairment Charges for the Fourth Quarter Ended June 30, 2013
Urologix, Inc. completed the acquisition of certain assets and Licenses related to Prostiva business from Medtronic VidaMed, Inc.
Urologix, Inc. Reports Revenue Results for the Fourth Quarter and Full Year of Fiscal 2013
Urologix, Inc. Primary Exchange Listing will Change to OTCQB Marketplace from Nasdaq Capital Market
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 902646 Aktie
  4. 902646 Aktie
  5. Nachrichten Urologix, Inc.
  6. Andere Sprachen